Suppr超能文献

表皮生长因子受体(ErbB)负调控机制及其在癌症中的相关性

Mechanisms of ErbB receptor negative regulation and relevance in cancer.

作者信息

Fry William H D, Kotelawala Lakmal, Sweeney Colleen, Carraway Kermit L

机构信息

UC Davis Cancer Center, Research Building III, Rm 1100B, 4645 2nd Avenue, Sacramento, California 95817, USA.

出版信息

Exp Cell Res. 2009 Feb 15;315(4):697-706. doi: 10.1016/j.yexcr.2008.07.022. Epub 2008 Jul 31.

Abstract

The ErbB family of receptor tyrosine kinases engages a wide variety of signaling pathways that collectively direct transcriptional programs controlling organogenesis during development and tissue maintenance in the adult. These receptors are also frequently found overexpressed or aberrantly activated in various cancers, suggesting that ErbB receptor signaling activity must be very tightly regulated. Sufficient levels of ErbB signaling are necessary to mediate tissue homeostasis, for example, but over-signaling can trigger cellular processes that contribute to cancer initiation or progression. Efforts over the last quarter century have led to a thorough understanding of the signaling pathways that are activated by these receptors and the mechanisms by which ErbB receptors engage these pathways. However, the compensatory negative regulatory mechanisms responsible for attenuating receptor activation have only more recently begun to be explored. Here we review the different known mechanisms of ErbB negative regulation, with particular emphasis on those proteins that exhibit some specificity for the ErbB family. We also describe how loss or suppression of ErbB negative regulators may contribute to tumor development, and discuss how restoration or augmentation of these pathways may represent a novel avenue for the development of ErbB-targeted therapies.

摘要

受体酪氨酸激酶的表皮生长因子受体(ErbB)家族参与多种信号通路,这些信号通路共同指导转录程序,控制发育过程中的器官形成以及成体中的组织维持。这些受体在各种癌症中也经常被发现过度表达或异常激活,这表明ErbB受体信号活性必须受到非常严格的调控。例如,足够水平的ErbB信号对于介导组织稳态是必要的,但过度信号传导会触发有助于癌症起始或进展的细胞过程。在过去的四分之一个世纪里,人们对这些受体激活的信号通路以及ErbB受体参与这些通路的机制有了透彻的了解。然而,负责减弱受体激活的补偿性负调控机制直到最近才开始被探索。在这里,我们回顾了已知的ErbB负调控的不同机制,特别强调那些对ErbB家族表现出一定特异性的蛋白质。我们还描述了ErbB负调控因子的缺失或抑制如何可能导致肿瘤发展,并讨论了这些通路的恢复或增强如何可能代表一种开发针对ErbB的治疗方法的新途径。

相似文献

1
Mechanisms of ErbB receptor negative regulation and relevance in cancer.
Exp Cell Res. 2009 Feb 15;315(4):697-706. doi: 10.1016/j.yexcr.2008.07.022. Epub 2008 Jul 31.
2
ErbB receptor negative regulatory mechanisms: implications in cancer.
J Mammary Gland Biol Neoplasia. 2006 Jan;11(1):89-99. doi: 10.1007/s10911-006-9015-3.
3
The ErbB receptors and their role in cancer progression.
Exp Cell Res. 2003 Mar 10;284(1):99-110. doi: 10.1016/s0014-4827(02)00099-x.
4
ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion.
Exp Cell Res. 2009 Feb 15;315(4):707-16. doi: 10.1016/j.yexcr.2008.10.034. Epub 2008 Nov 5.
5
Negative regulation of ErbB family receptor tyrosine kinases.
Br J Cancer. 2004 Jan 26;90(2):289-93. doi: 10.1038/sj.bjc.6601500.
7
Signal transduction and oncogenesis by ErbB/HER receptors.
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):903-13. doi: 10.1016/j.ijrobp.2003.06.002.
8
Cell signalling: growth factors and tyrosine kinase receptors.
Clin Transl Oncol. 2006 Feb;8(2):77-82. doi: 10.1007/s12094-006-0162-1.

引用本文的文献

2
Exploring the Role of CBX3 as a Potential Therapeutic Target in Lung Cancer.
Cancers (Basel). 2024 Aug 30;16(17):3026. doi: 10.3390/cancers16173026.
3
4
Diverse roles of epidermal growth factors receptors in oral and cutaneous canine melanomas.
BMC Vet Res. 2020 Jan 29;16(1):24. doi: 10.1186/s12917-020-2249-2.
6
Quantification of EGFR family in canine mammary ductal carcinomas in situ: implications on the histological graduation.
Vet Res Commun. 2019 May;43(2):123-129. doi: 10.1007/s11259-019-09752-0. Epub 2019 Apr 24.
10
Neoadjuvant therapy for early-stage breast cancer: the clinical utility of pertuzumab.
Cancer Manag Res. 2016 Feb 18;8:21-31. doi: 10.2147/CMAR.S55279. eCollection 2016.

本文引用的文献

1
Suppression of the negative regulator LRIG1 contributes to ErbB2 overexpression in breast cancer.
Cancer Res. 2008 Oct 15;68(20):8286-94. doi: 10.1158/0008-5472.CAN-07-6316.
2
Structural basis for EGFR ligand sequestration by Argos.
Nature. 2008 Jun 26;453(7199):1271-5. doi: 10.1038/nature06978. Epub 2008 May 25.
4
Inhibition of the EGF receptor by binding of MIG6 to an activating kinase domain interface.
Nature. 2007 Nov 29;450(7170):741-4. doi: 10.1038/nature05998.
5
EGF receptor ubiquitination is not necessary for its internalization.
Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):16904-9. doi: 10.1073/pnas.0707416104. Epub 2007 Oct 16.
6
The emerging shape of the ESCRT machinery.
Nat Rev Mol Cell Biol. 2007 May;8(5):355-68. doi: 10.1038/nrm2162.
7
Targeting of AMSH to endosomes is required for epidermal growth factor receptor degradation.
J Biol Chem. 2007 Mar 30;282(13):9805-9812. doi: 10.1074/jbc.M611635200. Epub 2007 Jan 29.
8
9
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Nature. 2007 Jan 25;445(7126):437-41. doi: 10.1038/nature05474. Epub 2007 Jan 7.
10
Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Cancer Res. 2006 Dec 1;66(23):11279-86. doi: 10.1158/0008-5472.CAN-06-2319.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验